Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya-Reference-Cited by-同舟云学术

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

Published:2019-02-23 Issue:1 Volume:220 Page:57-67
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Mutua Gaudensia¹,Anzala Omu¹,Luhn Kerstin²,Robinson Cynthia²,Bockstal Viki²,Anumendem Dickson²,Douoguih Macaya²

Affiliation:

1. Kenya AIDS Vaccine Initiative Institute of Clinical Research, College of Health Sciences, University of Nairobi, Kenya

2. Janssen Vaccines and Prevention, Leiden, the Netherlands

Funder

EBOVAC 1

EBOVAC 2

EBOMAN

BODAC

Janssen Vaccines and Prevention

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/220/1/57/28767147/jiz071.pdf

Reference33 articles.

1. A review of phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?;Lambe;Philos Trans R Soc Lond B Biol Sci,2017

2. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial;Milligan;JAMA,2016

3. Immune responses to novel adenovirus type 26 and modified vaccinia virus ankara-vectored Ebola vaccines at 1 year;Winslow;JAMA,2017

4. Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania;Anywaine;J Infect Dis,2019. .

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases;Nature Communications;2024-09-03

2. Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial;The Journal of Infectious Diseases;2024-07-16

3. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial;The Lancet Infectious Diseases;2024-07

4. Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial;Vaccines;2024-05-04

5. Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without Human Immunodeficiency Virus in Africa;Clinical Infectious Diseases;2024-04-24